Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Μargarita Papatheodoridi et al.|Journal of Hepatology|2022Cited by 121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expressionBisheng Liu, André Boonstra|Blood|2010Cited by 76
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Gastroenterology|2023Cited by 23